Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma [Thoracic Oncology]
Conclusions Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable rate of RP. Its incorporation with chemotherapy and P/D forms a new lung-sparing treatment paradigm for patients with locally advanced MPM. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Rimner, Zauderer, Gomez, Adusumilli, Parhar, Wu, Woo, Shen, Ginsberg, Yorke, Rice, Tsao, Rosenzweig, Rusch, Krug Tags: Radiation Oncology, Surgery, Radiation, Chemotherapy, Combined Modality Thoracic Oncology Source Type: research

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers [Breast Cancer]
Conclusion These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Schmidt, Hogervorst, van Hien, Cornelissen, Broeks, Adank, Meijers, Waisfisz, Hollestelle, Schutte, van den Ouweland, Hooning, Andrulis, Anton-Culver, Antonenkova, Antoniou, Arndt, Bermisheva, Bogdanova, Bolla, Brauch, Brenner, Bruning, Burwinkel, Chang-C Tags: Epidemiology, Statistical Genetics, Risk factors, Genetic epidemiology Breast Cancer Source Type: research

Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer [Breast Cancer]
Purpose Cardiovascular disease (CVD) is a leading cause of death among women with nonmetastatic breast cancer. Whether exercise is associated with reductions in CVD risk in patients with breast cancer with an elevated CVD risk phenotype is not known. Methods Using a prospective design, women (n = 2,973; mean age, 57 years) diagnosed with nonmetastatic breast cancer participating in two registry-based, regional cohort studies, completed a questionnaire that assessed leisure-time recreational physical activity (metabolic equivalent task [MET]-h/wk). The primary end point was the first occurrence of any of the following: new...
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Jones, Habel, Weltzien, Castillo, Gupta, Kroenke, Kwan, Quesenberry, Scott, Sternfeld, Yu, Kushi, Caan Tags: Epidemiology, Behavioral and Lifestyle Risk Factors Breast Cancer Source Type: research

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers [Gastrointestinal Cancer]
Conclusion In combination with cetuximab, ECF and FOLFOX had similar efficacy, but FOLFOX was better tolerated. Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Enzinger, Burtness, Niedzwiecki, Ye, Douglas, Ilson, Villaflor, Cohen, Mayer, Venook, Benson, Goldberg Tags: Chemotherapy Gastrointestinal Cancer Source Type: research

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial [Gastrointestinal Cancer]
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods We conducted an international (Australia and New Zealand, South Korea, and Canada) randomized phase II trial in which patients were randomly assigned at a two-to-one ratio and stratified by lines of prior chemotherapy for advanced disease (one v two) and region. Eligible patients received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred. The primary end point was ...
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Pavlakis, Sjoquist, Martin, Tsobanis, Yip, Kang, Bang, Alcindor, OCallaghan, Burnell, Tebbutt, Rha, Lee, Cho, Lipton, Wong, Strickland, Kim, Zalcberg, Simes, Goldstein Tags: Chemotherapy Gastrointestinal Cancer Source Type: research

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial [Gastrointestinal Cancer]
Purpose The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification of patients at risk for relapse remains challenging. We evaluated whether pathologic response and lymph node status after neoadjuvant chemotherapy are prognostic in patients treated in the MAGIC trial. Materials and Methods Pathologic regression was assessed in resection specimens by two independent pathologists using the Mandard tumor regression grading sy...
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Smyth, Fassan, Cunningham, Allum, Okines, Lampis, Hahne, Rugge, Peckitt, Nankivell, Langley, Ghidini, Braconi, Wotherspoon, Grabsch, Valeri Tags: Clinical Trials, Prognostic Studies, Diagnosis & Staging, Surgery, Chemotherapy, Combined Modality Gastrointestinal Cancer Source Type: research

Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer [Treatment-Related Complications]
Purpose Cisplatin is widely used but highly ototoxic. Effects of cumulative cisplatin dose on hearing loss have not been comprehensively evaluated in survivors of adult-onset cancer. Patients and Methods Comprehensive audiological measures were conducted on 488 North American male germ cell tumor (GCT) survivors in relation to cumulative cisplatin dose, including audiograms (0.25 to 12 kHz), tests of middle ear function, and tinnitus. American Speech-Language-Hearing Association criteria defined hearing loss severity. The geometric mean of hearing thresholds (0.25 to 12 kHz) summarized overall hearing status consistent wi...
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Frisina, Wheeler, Fossa, Kerns, Fung, Sesso, Monahan, Feldman, Hamilton, Vaughn, Beard, Budnick, Johnson, Ardeshir-Rouhani-Fard, Einhorn, Lipshultz, Dolan, Travis Tags: Chemotherapy, Outcomes Research Treatment-Related Complications Source Type: research

Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer [Urologic Oncology]
Conclusion PSA levels in midlife strongly predict future lethal PCa in a US cohort subject to opportunistic screening. Risk-stratified screening on the basis of midlife PSA should be considered in men age 45 to 59 years. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Preston, Batista, Wilson, Carlsson, Gerke, Sjoberg, Dahl, Sesso, Feldman, Gann, Kibel, Vickers, Mucci Tags: Epidemiology & Prevention Urologic Oncology Source Type: research

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study [Hematologic Malignancy]
Conclusion Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Lesokhin, Ansell, Armand, Scott, Halwani, Gutierrez, Millenson, Cohen, Schuster, Lebovic, Dhodapkar, Avigan, Chapuy, Ligon, Freeman, Rodig, Cattry, Zhu, Grosso, Bradley Garelik, Shipp, Borrello, Timmerman Tags: Non-Hodgkin's Lymphoma Hematologic Malignancy Source Type: research

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome [Rapid Communication]
Conclusion PD-L1/PD-L2 alterations are a defining feature of cHL. Amplification of 9p24.1 is more common in patients with AS disease and associated with shorter PFS in this series. Further analyses of 9p24.1 alterations in patients treated with standard cHL induction regimens or checkpoint blockade are warranted. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Roemer, Advani, Ligon, Natkunam, Redd, Homer, Connelly, Sun, Daadi, Freeman, Armand, Chapuy, de Jong, Hoppe, Neuberg, Rodig, Shipp Tags: Biology & Immunology, Rapid Communications, Rapid Communications Source Type: research

The Sound of Silence: A Proxy for Platinum Toxicity [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Oldenburg, Gietema Tags: Supportive Care, Chemotherapy, Outcomes Research, Quality of Life EDITORIALS Source Type: research

Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Loeb Tags: Diagnosis & Staging EDITORIALS Source Type: research

From Illumination to Innovation: Visualizing the Future--The 2015 Presidential Address [PRESIDENTIAL ADDRESS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Yu Tags: PRESIDENTIAL ADDRESS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Reply to D.E. Spratt and N. Szerlip [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Rades, Schild Tags: CORRESPONDENCE Source Type: research

Comparing Two Multifraction Spine Radiotherapy Regimens: Are They Really Equivalent? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Spratt, Szerlip Tags: CORRESPONDENCE Source Type: research

Reply to B. Abderrahman and V. C. Jordan [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Lamm, Kostler Tags: CORRESPONDENCE Source Type: research

Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Abderrahman, Jordan Tags: CORRESPONDENCE Source Type: research

Reply to E. Avisar, H. Kuerer, L. Livi et al, and E. Hindie et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Thorsen, Offersen, Overgaard Tags: CORRESPONDENCE Source Type: research

Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Hindie, Groheux Tags: CORRESPONDENCE Source Type: research

Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Livi, Meattini, Kaidar-Person, Poortmans Tags: CORRESPONDENCE Source Type: research

Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Kuerer Tags: CORRESPONDENCE Source Type: research

Internal Mammary Node Irradiation: Does One Treatment Fit All? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Avisar Tags: CORRESPONDENCE Source Type: research

Regarding Beau [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Meyer Tags: Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose To provide evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer. Methods American Society of Clinical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology, gastroenterology, palliative care, and advocacy experts and conducted a systematic review of the literature from January 2002 to June 2015. Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. Results Twenty-six randomized controlled trials met the systematic review criteria. Recommend...
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Balaban, Mangu, Khorana, Shah, Mukherjee, Crane, Javle, Eads, Allen, Ko, Engebretson, Herman, Strickler, Benson, Urba, Yee Tags: ASCO Guidelines, Diagnosis & Staging, Radiation, Chemotherapy, Palliative Care ASCO SPECIAL ARTICLE Source Type: research

Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia [Treatment-Related Complications]
Purpose To examine associations among methotrexate pharmacodynamics, neuroimaging, and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy-only protocol. Patients and Methods This longitudinal study linked pharmacokinetic assays collected during therapy to neurocognitive and brain imaging outcomes during long-term follow-up. A total of 218 (72.2%) of 302 eligible long-term survivors were recruited for outcome studies when they were more than 5 years post-diagnosis and older than 8 years of age. At long-term follow-up, survivors were an average of ...
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Krull, Cheung, Liu, Fellah, Reddick, Brinkman, Kimberg, Ogg, Srivastava, Pui, Robison, Hudson Tags: Chemotherapy, Acute Lymphoblastic Leukemia, Long Term Survival & Late Effects, Outcomes Research Treatment-Related Complications Source Type: research

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer [Urologic Oncology]
Purpose Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC). This phase III study was conducted to confirm the phase II results and to detect an overall survival (OS) benefit. Patients and Methods Men with chemotherapy-naïve mCRPC and evidence of bone metastases were assigned (2:1) to receive tasquinimod once per day or placebo until progression or toxicity. The primary end point was radiographic PFS (rPFS; time from random as...
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Sternberg, Armstrong, Pili, Ng, Huddart, Agarwal, Khvorostenko, Lyulko, Brize, Vogelzang, Delva, Harza, Thanos, James, Werbrouck, Bogemann, Hutson, Milecki, Chowdhury, Gallardo, Schwartsmann, Pouget, Baton, Nederman, Tuvesson, Carducci Tags: Systemic Therapy Urologic Oncology Source Type: research

Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement [Urologic Oncology]
Conclusion A subset of patients with cN+ bladder cancer achieves long-term survival. Combined-modality therapy, with chemotherapy and cystectomy, is associated with the best outcomes. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Galsky, Stensland, Sfakianos, Mehrazin, Diefenbach, Mohamed, Tsao, Boffetta, Wiklund, Oh, Mazumdar, Ferket Tags: Surgery, Chemotherapy, Combined Modality Therapy Urologic Oncology Source Type: research

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma [Melanoma]
Conclusion T-VEC with ipilimumab had a tolerable safety profile, and the combination appeared to have greater efficacy than either T-VEC or ipilimumab monotherapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Puzanov, Milhem, Minor, Hamid, Li, Chen, Chastain, Gorski, Anderson, Chou, Kaufman, Andtbacka Tags: Combined Modality Melanoma Source Type: research

Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer [Breast Cancer]
Purpose Racial disparities in BRCA1/2 testing have been documented, but causes of these disparities are poorly understood. The study objective was to investigate whether the distribution of black and white patients across cancer providers contributes to disparities in BRCA1/2 testing. Patients and Methods We conducted a population-based study of women in Pennsylvania and Florida who were 18 to 64 years old and diagnosed with invasive breast cancer between 2007 and 2009, linking cancer registry data, the American Medical Association Physician Masterfile, and patient and physician surveys. The study included 3,016 women (69...
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: McCarthy, Bristol, Domchek, Groeneveld, Kim, Motanya, Shea, Armstrong Tags: Diagnosis & Staging Breast Cancer Source Type: research

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) [Breast Cancer]
Conclusion The addition of bevacizumab to letrozole improved PFS in hormone receptor–positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on predictive markers will be required to clarify the role of bevacizumab in this setting. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Dickler, Barry, Cirrincione, Ellis, Moynahan, Innocenti, Hurria, Rugo, Lake, Hahn, Schneider, Tripathy, Carey, Winer, Hudis Tags: Hormonal Therapy Breast Cancer Source Type: research

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group [Pediatric Oncology]
Conclusion Chemotherapy was substantially reduced safely in one-quarter of children with ALL who were selected on the basis of undetectable MRD levels, without jeopardizing the survival rate. Outcomes of patients with intermediate and high levels of MRD improved with therapy intensification. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Pieters, de Groot-Kruseman, Van der Velden, Fiocco, van den Berg, de Bont, Egeler, Hoogerbrugge, Kaspers, Van der Schoot, De Haas, Van Dongen Tags: Acute Lymphoblastic Leukemia Pediatric Oncology Source Type: research

Biomarker Panel for Chronic Graft-Versus-Host Disease [Hematologic Malignancy]
Conclusion We conclude that the biomarker panel measured at diagnosis or day +100 after HCT may allow patient stratification according to risk of cGVHD. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Yu, Storer, Kushekhar, Abu Zaid, Zhang, Gafken, Ogata, Martin, Flowers, Hansen, Arora, Cutler, Jagasia, Pidala, Hamilton, Chen, Pusic, Lee, Paczesny Tags: Leukemia Hematologic Malignancy Source Type: research

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial [Hematologic Malignancy]
Purpose To study the outcome of histologic transformation (HT) in a large prospective cohort of patients with follicular lymphoma (FL) who previously responded to immunochemotherapy. Patients and Methods After a median 6-year follow-up of 1,018 randomly assigned patients from the PRIMA trial, disease progression was observed in 463 patients, 194 of whom had histologic documentation. Results Forty patients had histology consistent with HT, and 154 had untransformed FL (median time to recurrence, 9.6 v 22.8 months, respectively; P = .018). Thirty-seven percent of biopsies performed during the first year of follow-up showed...
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Sarkozy, Trneny, Xerri, Wickham, Feugier, Leppa, Brice, Soubeyran, Gomes Da Silva, Mounier, Offner, Dupuis, Caballero, Canioni, Paula, Delarue, Zachee, Seymour, Salles, Tilly Tags: Risk factors, Epidemiology, Diagnosis & Staging, Chemotherapy Hematologic Malignancy Source Type: research

No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial [Rapid Communication]
Conclusion To the best of our knowledge, this is the first long-term analysis confirming that GnRHa is not efficient in preventing chemotherapy-induced POF in young patients with lymphoma and did not influence future pregnancy rate. These results reopen the debate about the drug’s benefit in that it should not be recommended as standard for fertility preservation in patients with lymphoma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Demeestere, Brice, Peccatori, Kentos, Dupuis, Zachee, Casasnovas, Van Den Neste, Dechene, De Maertelaer, Bron, Englert Tags: Quality of Life, Menopausal Symptoms, Rapid Communications Source Type: research

Will a Better Understanding of the Problem With Transformed Follicular Lymphoma Lead to Better Outcomes? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Link Tags: Diagnosis & Staging EDITORIALS Source Type: research

Appraising the Biological Evidence for and Against the Utility of GnRHa for Preservation of Fertility in Patients With Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Oktay, Bedoschi Tags: Quality of Care EDITORIALS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Reply to H. Laubli et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Macbeth, Noble Tags: CORRESPONDENCE Source Type: research

Antimetastatic Properties of Low Molecular Weight Heparin [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Laubli, Varki, Borsig Tags: CORRESPONDENCE Source Type: research

Reply to C.S. Hourigan et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Bassan Tags: CORRESPONDENCE Source Type: research

When the Minimal Becomes Measurable [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Hourigan, Goswami, Battiwalla, Barrett, Sheela, Karp, Lai Tags: CORRESPONDENCE Source Type: research

Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015. Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. Results Nine randomized controlled trials met the systematic review criteria. Recommendations A multiphase computed tomography scan of the abdomen and pelvis ...
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Khorana, Mangu, Berlin, Engebretson, Hong, Maitra, Mohile, Mumber, Schulick, Shapiro, Urba, Zeh, Katz Tags: ASCO Guidelines, Diagnosis & Staging, Surgery, Radiation, Chemotherapy ASCO SPECIAL ARTICLE Source Type: research

Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use [STATISTICS IN ONCOLOGY]
The decision curve is a graphical summary recently proposed for assessing the potential clinical impact of risk prediction biomarkers or risk models for recommending treatment or intervention. It was applied recently in an article in Journal of Clinical Oncology to measure the impact of using a genomic risk model for deciding on adjuvant radiation therapy for prostate cancer treated with radical prostatectomy. We illustrate the use of decision curves for evaluating clinical- and biomarker-based models for predicting a man’s risk of prostate cancer, which could be used to guide the decision to biopsy. Decision curves ...
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Kerr, Brown, Zhu, Janes Tags: Prognostic Studies, Risk factors STATISTICS IN ONCOLOGY Source Type: research

Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer [Thoracic Oncology]
Purpose A confirmatory analysis was performed to determine the prognostic value of metabolic response during induction chemotherapy followed by bimodality/trimodality treatment of patients with operable locally advanced non–small-cell lung cancer. Patients and Methods Patients with potentially operable stage IIIA(N2) or selected stage IIIB non–small-cell lung cancer received three cycles of cisplatin/paclitaxel (induction chemotherapy) followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine) within the ESPATUE (Phase III Study of Surgery Versus Definitive...
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Pottgen, Gauler, Bellendorf, Guberina, Bockisch, Schwenzer, Heinzelmann, Cordes, Schuler, Welter, Stamatis, Friedel, Darwiche, Jockel, Eberhardt, Stuschke Tags: Combined Modality, Nuclear Medicine Thoracic Oncology Source Type: research

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE) [Gynecologic Cancer]
Conclusion Although the primary objective was not met, subgroup analyses showed trends in PFS favoring pertuzumab in the gemcitabine and paclitaxel cohorts, meriting further exploration of pertuzumab in ovarian cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Kurzeder, Bover, Marme, Rau, Pautier, Colombo, Lorusso, Ottevanger, Bjurberg, Marth, Barretina-Ginesta, Vergote, Floquet, del Campo, Mahner, Bastiere-Truchot, Martin, Oestergaard, Kiermaier, Schade-Brittinger, Polleis, du Bois, Gonzalez-Martin Tags: Chemotherapy, Combined Modality Gynecologic Cancer Source Type: research

Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia [Pediatric Oncology]
Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for low bone mineral density (BMD) and frail health, outcomes potentially modifiable by altering health behaviors and/or treating endocrine abnormalities. We evaluated associations between lifestyle and hormonal deficits with risk of low BMD and frailty among survivors of ALL. Patients and Methods Participants included 862 survivors of ALL (median age, 31.3 years [range, 18.4 to 59.7 years]) enrolled in the St Jude Lifetime Cohort study. Bone density was measured using quantitative computed tomography of L1 through L2 vertebrae; low BMD was defi...
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Wilson, Chemaitilly, Jones, Kaste, Srivastava, Ojha, Yasui, Pui, Robison, Hudson, Ness Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research

Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study [Gastrointestinal Cancer]
Conclusion Aspirin use after the diagnosis of CRC is independently associated with improved CSS and OS. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Bains, Mahic, Myklebust, Smastuen, Yaqub, Dorum, Bjornbeth, Moller, Brudvik, Tasken Tags: Chemoprevention studies, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Combined Modality, Translational Oncology, Gastrointestinal Gastrointestinal Cancer Source Type: research